QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

NCT07110064 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Advance Pancreatic Cancer

Interventions

DRUG: QL1706+Lenvatinib+AG Regimen

Sponsor

Du Juan